Filing Flows › Jaguar Health (JAGX) › Q1 2025
Jaguar Health (JAGX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Jaguar Health (JAGX) reported revenue of $2.2M for the first quarter 2025 (Q1 2025), -6% from a year earlier and -37% from the quarter before. Operating margin was -425.5%, net loss $10.6M (478.6% of revenue).
Jaguar Health, Q1 2025: revenue $2.2M (-6% year over year), operating margin -425.5%, net loss $10.6M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.2M | -37% | -6% |
| Operating profit | −$9.4M | — | — |
| Net earnings | −$10.6M | — | — |
| Operating cash flow | −$7.3M | — | — |
What changed
Revenue was $2.2M in Q1 2025, down 6% year over year and down 37% from the previous quarter. Product was the largest line at 98% of revenue. Product lost $180K year over year (down 8%), 131% of the total change.
Operating costs exceeded revenue by $9.4M, an operating margin of -425.5%. Total costs grew 10% against a revenue fall of 6%. The fastest-growing cost line was Sales & marketing (+73%). The quarter ended with a net loss of $10.6M, wider than the previous quarter's $10.2M loss. Minority interests bore $132K of it: to shareholders the quarter was a loss of $10.5M.
Operating cash flow was −$7.3M. Non-cash charges added back $479K of depreciation and amortization and $301K of share-based compensation. Working capital and other items added $2.5M.
Questions
What was Jaguar Health's revenue in the first quarter 2025?
Jaguar Health (JAGX) reported revenue of $2.2M for the first quarter 2025 (Q1 2025), -6% from a year earlier and -37% from the quarter before.
Was Jaguar Health profitable in the first quarter 2025?
Operating loss was $9.4M (-425.5% of revenue) and net loss $10.6M.
Source: Jaguar Health 10-Q on SEC EDGAR.